web analytics
September 3, 2014 / 8 Elul, 5774
At a Glance

Posts Tagged ‘Teva’

Teva Wins FDA Approval for Leukemia Drug

Thursday, February 13th, 2014

The U.S. Food and Drug Administration (FDA) has granted Israeli-based Teva Pharmaceuticals full approval for Synribo, a drug that is injected for adults with a with chronic phase or accelerated phase of myeloid leukemia.

Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is one of four main types of leukemia and is a cancer of the blood and bone marrow.

The FDA had given initial approval for the drug in October 2012 but said Teva had to provide additional clinical trial data before it could bring the drug to market.

“With this approval, based on the final analysis of two Phase II trials that evaluated efficacy and tolerability data of Synribo, we believe healthcare providers can be even more confident in the clinical profile of this important medicine, said Teva president and CEO global specialty medicines Rob Koremans.

Teva Names New CEO Three Months after Firing Jeremy Levin

Thursday, January 9th, 2014

Teva Pharmaceutical announced on Thursday that its new CEO will be Erez Vigodman, who until now has been the CEO for the huge phosphate and chemical producer Makhteshim Agan Industries.

Vigodman replaces Dr. Jeremy Levin, who moved to Israel two years to take over the world’s largest generic drug company, which has been faltering since a rival firm began marketing a generic alternative to Teva’s conventional Copaxone drug that prevents the reoccurrence of Muscular Sclerosis.

Levin was fired after arguments on company strategy between him and the board of directors.

Teva chairman Dr. Phillip Frost said, “As a member of the Teva board since 2009, Erez has a deep understanding of the company and the industry in which it operates, putting him in a strong position to hit the ground running and deliver value for shareholders.”

Ex-Teva CEO Jeremy Levin Says He Is Staying in Israel – for Now

Wednesday, November 20th, 2013

Jeremy Levin, who moved to Israel last year to take over the helm at Teva Pharmaceuticals only to be fired last month, say he loves Israel and is staying here, at least for the time being.

Unlike Stanley Fischer, who made aliya to take over the post of Governor of the Bank of Israel and then packed up and left earlier this year, Levin is a lot more outgoing an expresses himself on a more personal level.

“I intend to devote my time in the short term to get to know Israel and Israelis, and to see everything that this country has to offer,” Levin told graduates in the masters program for business administration at Tel Aviv University Tuesday.

“There is special warmth and love in Israel, and I’m proud to be an Israeli,” he added. “Follow your hearts, dream big, learn from mistakes and appreciate the loss in order to learn from it.”

He also said he looking for work.

“As for myself, I immigrated and I’m now unemployed, so if you have some interesting offers…,” Levin told the graduates.

Levine expressed the same views as  Fischer and his successor Karnit Flug that Israel needs to “educate all sectors of society and include all the nations: Christians, Jews, Muslims, groups such as the Haredim, the Druze, everyone. Everyone should be an important contribution to the economy.

Teva to Fire 5,000 Workers Worldwide

Thursday, October 10th, 2013

Israel’s giant generic Teva Pharmaceuticals firm will fire  by the end of next year 5,000 employees around the world, including hundreds in Israel, as one of the “steps to accelerate the reduction of costs and to optimize its structure.”

Most of the layoffs will be outside Israel, said Teva CEO Jeremy Levin, who moved to Israel form the United States last year to head the company.

The layoffs are expected to save the company $1.5 to $2 billion by the end of 2017, and part of the savings will be re-invested in the development of generic and specialty drugs.

Levin maintained  that the company is not suffering from financial problems. In New York, the company’s shares jumped 2 percent on news of the cutback in the workforce.

Teva’s stock was the darling of investors until five years ago, when the announcement of competitors’  generic drugs to replace Teva’s patented Copaxone drug, which treats  multiple sclerosis, drove the stock down by nearly 50 percent.

Another Israel Pharmaceutical Firm Goes to NASDAQ

Wednesday, October 9th, 2013

Kitov Pharmaceuticals accounted it plans to apply for listing on the NASDAQ exchange, joining Israel-based Teva and Kamada that are traded on Wall Street.

Kitov is hoping for approval from the U.S. Food and Drug Administration (FDA) after its Phase III clinical trial of a combination drug for the treatment of hypertension and pain relief.

The drug has a potential market of $10 billion, and the company’s stock in Israel has climbed almost 10-fold this year.

It also is developing a combination drug for the treatment of osteoarthritis, with the risk of hypertension and other side effects associated with current treatments, Globes reported.

Paris Prosecutor Says No Zopiclone in Teva Furosemide Tablets

Wednesday, July 3rd, 2013

The pharmaceutical giant Teva’s French division, Teva France, announced that the preliminary investigation conducted by the Paris Prosecutor resulted in the conclusion that there were no signs of Zopiclone in Furosemide tablets manufactured by Teva.

Therefore, the prosecutor decided that there is no connection between the Teva plant in Sens, France, where the drug Furosemide 40 mg was packed and the apparent substitution of those tablets, as was reported by a pharmacist in the town of Saint-Malo.

Two elderly women, 89- and 100-years-old, died last month in France after reportedly taking Furosemide 40 mg that was manufactured by Teva.

The case involves Zopiclone which was mistakenly sold in packaging for Furosemide. Teva says that the error was discovered by a pharmacist, after a patient who took the medication suffered from unusual sleepiness. A test found that the incident involved two problematic packages, which the company recalled.

President and CEO of Teva, Dr. Jeremy Levin, stated that ” the results of the investigation clears Teva of all suspicion of operational failure. For Teva, the well being and safety of patients are top priority, and we are committed to adhering to the highest standards in manufacturing and complying with all relevant regulations.”

Teva to Sell Generic Viagra in UK, and Move Patent Filing to Switzerland

Sunday, June 23rd, 2013

Teva, the world leader in generic medication will be soon be launching a generic version of Pfizer’s Viagra in the UK and Europe.

Pfizer’s Viagra patents expired this past week in the UK and parts of Europe, allowing other manufacturers to move in.

In the US, a court ruling has prevented Teva from introducing generic Viagra until at least 2020.

Teva also announced that it will stop filing its patents in Israel, and will now be filing them instead in Switzerland.

The reason for the move are Switzerland’s patent related tax laws, and subsequent tax breaks and benefits they will provide Teva.

Teva said that if Israel were to change its tax codes to make them more competitive with other countries, they’d be happy to move the IP registrations back to Israel, according to a report in Globes.

Printed from: http://www.jewishpress.com/news/breaking-news/teva-to-sell-generic-viagra-in-uk-and-move-patents-to-switzerland/2013/06/23/

Scan this QR code to visit this page online: